{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:03:07Z","timestamp":1792735387033,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The goal of this review is to provide practical guidance for gastroenterologists regarding diagnosis and management of inflammatory bowel disease associated spondyloarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>While there is limited data regarding optimal management approaches, we summarize available screening tools along with classification and consensus criteria that can be deployed in this setting and offer guidance regarding patient symptoms, physical exam findings, laboratory data, and imaging strategies that may facilitate diagnosis. In addition, we outline various therapeutic options available while highlighting deficits in the currently available literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Inflammatory bowel disease associated spondyloarthritis is common but remains poorly understood. Ongoing research to establish a clear diagnostic pathway and reproducible treatment targets is essential to better identify and treat this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11894-025-00990-8","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:31:15Z","timestamp":1752503475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Practical Tips for Diagnosis and Management of Concomitant Inflammatory Spondyloarthritis and Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Katherine","family":"Falloon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Forney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Cheemalavagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"990_CR1","doi-asserted-by":"crossref","unstructured":"Vavricka SR, Brun L, Ballabeni P, Pittet V, Vavricka BMP, Zeitz J et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1).","DOI":"10.1038\/ajg.2010.343"},{"key":"990_CR2","doi-asserted-by":"crossref","unstructured":"Falloon K, Forney M, Husni ME, Feagan B, Rieder F. Diagnosis and management of inflammatory bowel Disease-Associated spondyloarthritis. Am J Gastroenterol. 2024;120(1).","DOI":"10.14309\/ajg.0000000000003092"},{"key":"990_CR3","doi-asserted-by":"crossref","unstructured":"Falloon K, Dossaji Z, Mude P, Bhalla J, Bhattacharya A, Cheemalavagu S, et al. Diagnosis of inflammatory bowel Diseases-Associated peripheral spondyloarthritis: A systematic Reiew. Inflamm Bowel Dis J. 2024;31(3).","DOI":"10.1093\/ibd\/izae114"},{"issue":"11","key":"990_CR4","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s11136-016-1345-z","volume":"25","author":"X Yang","year":"2016","unstructured":"Yang X, Fan D, Xia Q, Wang M, Zhang X, Li X, et al. The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. Qual Life Res. 2016;25(11):2711\u201323.","journal-title":"Qual Life Res"},{"key":"990_CR5","doi-asserted-by":"crossref","unstructured":"Ghosh S, Casellas F, O\u2019Shea C, Leonard M, Petersson J, Peyrin-Biroulet L. P410 extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC. J Crohns Colitis. 2019;13(Supplement_1).","DOI":"10.1093\/ecco-jcc\/jjy222.534"},{"issue":"9","key":"990_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-020-00932-5","volume":"22","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou E, Ramiro S. Work disability in axial spondyloarthritis. Curr Rheumatol Rep. 2020;22(9):55.","journal-title":"Curr Rheumatol Rep"},{"key":"990_CR7","unstructured":"Falloon K, Abushamma S, Ananthakrishnan A, Barnes E, Bhattacharya A, Cross RK, et al. Inflammatory bowel disease (IBD)-Associated peripheral arthritis is not associated with objective markers of luminal IBD disease Activity - Results from the CHASE cohort. ACG Abstract. 2024;19(Supplement_1)."},{"issue":"12","key":"990_CR8","first-page":"2860","volume":"27","author":"K de Vlam","year":"2000","unstructured":"de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27(12):2860\u20135.","journal-title":"J Rheumatol"},{"key":"990_CR9","doi-asserted-by":"crossref","unstructured":"Hedin CRH, Vavricka SR, Stagg AJ, Schoepfer A, Raine T, Puig L et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis. 2019;13(5).","DOI":"10.1093\/ecco-jcc\/jjy191"},{"issue":"11","key":"990_CR10","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1136\/annrheumdis-2019-216456","volume":"80","author":"G Guggino","year":"2021","unstructured":"Guggino G, Rizzo A, Mauro D, Macaluso F, Ciccia F. Gut-derived CD8 + tissue-resident memory T cells are expanded in the peripheral blood and synovia of spa patients. Ann Rheum Dis. 2021;80(11):e174.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"990_CR11","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/annrheumdis-2016-211064","volume":"76","author":"M Breban","year":"2017","unstructured":"Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiocchia G, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76(9):1614\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"990_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","volume":"161","author":"G Rogler","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118\u201332.","journal-title":"Gastroenterology"},{"issue":"12","key":"990_CR13","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/ecco-jcc\/jjaa096","volume":"14","author":"A Variola","year":"2020","unstructured":"Variola A, Zanolin ME, Cipriano G, Macchioni P, Martinis F, Pasetti A, et al. The IBIS-Q [IBd Identification of Spondyloarthritis Questionnaire]: A Novel Tool to Detect Both Axial and Peripheral Arthritis in Inflammatory Bowel Disease Patients. J Crohns Colitis. 2020;14(12):1680\u20136.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"990_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3899\/jrheum.200364","volume":"48","author":"D Benfaremo","year":"2021","unstructured":"Benfaremo D, Luchetti MM, Di Carlo M, Lagan\u00e0 B, Picchianti-Diamanti A, Carubbi F, et al. Multicenter validation of the DETAIL questionnaire for the screening of spondyloarthritis in patients with inflammatory bowel diseases. J Rheumatol. 2021;48(2):179\u201387.","journal-title":"J Rheumatol"},{"key":"990_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8618703","volume":"2018","author":"R Queiro","year":"2018","unstructured":"Queiro R, Rodr\u00edguez-Caminero S, Riestra S, de Francisco R, P\u00e9rez-Mart\u00ednez I, Ballina J. Performance of two screening questionnaires for inflammatory arthritis in patients with inflammatory bowel disease. Biomed Res Int. 2018;2018:1\u20135.","journal-title":"Biomed Res Int"},{"key":"990_CR16","doi-asserted-by":"crossref","unstructured":"Falloon K, Cohen B, Ananthakrishnan AN, Barnes EL, Bhattacharya A, Colombel J, et al. A united States expert consensus to standardise definitions, follow-up, and treatment targets for extra\u2010intestinal manifestations in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(9).","DOI":"10.1111\/apt.16853"},{"issue":"3","key":"990_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"TR Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387\u201391.","journal-title":"Gut"},{"issue":"1","key":"990_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1\u201337.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"990_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S2468-1253(21)00297-1","volume":"7","author":"L Guillo","year":"2022","unstructured":"Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, et al. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the international organization for the study of inflammatory bowel diseases. Lancet Gastroenterol Hepatol. 2022;7(3):254\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"990_CR20","doi-asserted-by":"crossref","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3).","DOI":"10.1093\/ecco-jcc\/jjv213"},{"issue":"1","key":"990_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M van der Rudwaleit","year":"2011","unstructured":"van der Rudwaleit M, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"990_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M van der Rudwaleit","year":"2009","unstructured":"van der Rudwaleit M, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"990_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/gut.17.11.906","volume":"17","author":"EG Mallas","year":"1976","unstructured":"Mallas EG, Mackintosh P, Asquith P, Cooke WT. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut. 1976;17(11):906\u201310.","journal-title":"Gut"},{"issue":"7","key":"990_CR24","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/rheumatology\/keq447","volume":"50","author":"F Bandinelli","year":"2011","unstructured":"Bandinelli F, Milla M, Genise S, Giovannini L, Bagnoli S, Candelieri A, et al. Ultrasound discloses entheseal involvement in inactive and low active inflammatory bowel disease without clinical signs and symptoms of spondyloarthropathy. Rheumatology. 2011;50(7):1275\u20139.","journal-title":"Rheumatology"},{"issue":"3","key":"990_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semarthrit.2020.01.001","volume":"50","author":"E Bertolini","year":"2020","unstructured":"Bertolini E, Macchioni P, Rizzello F, Salice M, Vukatana G, Sandri G, et al. Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients. Semin Arthritis Rheum. 2020;50(3):436\u201343.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"990_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/art.10812","volume":"48","author":"MA D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power doppler: A cross-sectional study. Arthritis Rheum. 2003;48(2):523\u201333.","journal-title":"Arthritis Rheum"},{"issue":"1suppl","key":"990_CR27","doi-asserted-by":"publisher","first-page":"S658","DOI":"10.1177\/1947603520968204","volume":"13","author":"T Duzenli","year":"2021","unstructured":"Duzenli T, Ata E, Kosem M. Ultrasonographic assessment of knee cartilage thickness in patients with ulcerative colitis: decreased femoral cartilage thickness May be an Indicator of extraintestinal manifestation in patients with mild activity ulcerative colitis. Cartilage. 2021;13(1suppl):S658\u201364.","journal-title":"Cartilage"},{"issue":"1","key":"990_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejr.2012.09.004","volume":"35","author":"Y Ezzat","year":"2013","unstructured":"Ezzat Y, Gaber W, Abd EL-Rahman SF, Ezzat M, El Sayed M. Ultrasonographic evaluation of lower limb enthesis in patients with early spondyloarthropathies. Egypt Rheumatologist. 2013;35(1):29\u201335.","journal-title":"Egypt Rheumatologist"},{"issue":"4","key":"990_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jmu.2014.03.004","volume":"22","author":"YF Hsiao","year":"2014","unstructured":"Hsiao YF, Wei SC, Lu CH, Wu CH, Hsieh SC, Li KJ. Patients with inflammatory bowel disease have higher sonographic enthesitis scores than normal individuals: pilot study in Taiwan. J Med Ultrasound. 2014;22(4):194\u20139.","journal-title":"J Med Ultrasound"},{"key":"990_CR30","doi-asserted-by":"crossref","unstructured":"Husic R, Lackner A, Kump PK, H\u00f6genauer C, Graninger W, Dejaco C. High prevalence of ultrasound verified enthesitis in patients with inflammatory bowel disease with or without spondylarthritis. Front Med (Lausanne). 2021;8.","DOI":"10.3389\/fmed.2021.637459"},{"issue":"10","key":"990_CR31","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1093\/rheumatology\/keaa036","volume":"59","author":"F Martinis","year":"2020","unstructured":"Martinis F, Tinazzi I, Bertolini E, Citriniti G, Variola A, Geccherle A, et al. Clinical and sonographic discrimination between fibromyalgia and spondyloarthopathy in inflammatory bowel disease with musculoskeletal pain. Rheumatology. 2020;59(10):2857\u201363.","journal-title":"Rheumatology"},{"issue":"1","key":"990_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00296-022-05208-y","volume":"43","author":"S Ottaviani","year":"2022","unstructured":"Ottaviani S, Tr\u00e9ton X, Forien M, Coralli R, Dauchez A, Stefanescu C, et al. Screening for spondyloarthritis in patients with inflammatory bowel diseases. Rheumatol Int. 2022;43(1):109\u201317.","journal-title":"Rheumatol Int"},{"issue":"1","key":"990_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12891-016-0932-z","volume":"17","author":"J Rovisco","year":"2016","unstructured":"Rovisco J, Duarte C, Batticcioto A, Sarzi-Puttini P, Dragresshi A, Portela F, et al. Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study. BMC Musculoskelet Disord. 2016;17(1):84.","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"990_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.7547\/87507315-76-8-439","volume":"76","author":"FJ Bartolomei","year":"1986","unstructured":"Bartolomei FJ. Pedal manifestations of the seronegative spondyloarthritides. Part IV: enteropathic arthropathy of crohn\u2019s disease. J Am Podiatr Med Assoc. 1986;76(8):439\u201344.","journal-title":"J Am Podiatr Med Assoc"},{"issue":"5","key":"990_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3109\/03009742.2014.882407","volume":"43","author":"L Brakenhoff","year":"2014","unstructured":"Brakenhoff L, Stomp W, van Gaalen F, Hommes D, van der Bloem J, et al. Magnetic resonance imaging of the hand joints in patients with inflammatory bowel disease and arthralgia: a pilot study. Scand J Rheumatol. 2014;43(5):416\u20138.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"990_CR36","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ecco-jcc\/jjae022","volume":"18","author":"N Vladimirova","year":"2024","unstructured":"Vladimirova N, Terslev L, Attauabi M, Madsen G, Fana V, Wiell C, et al. Peripheral joint and enthesis involvement in patients with newly diagnosed inflammatory bowel disease: symptoms, and clinical and ultrasound Findings\u2013 A Population-Based cohort study. J Crohns Colitis. 2024;18(7):1053\u201370.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"990_CR37","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3899\/jrheum.140878","volume":"41","author":"AM Orbai","year":"2014","unstructured":"Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol. 2014;41(11):2290\u20134.","journal-title":"J Rheumatol"},{"issue":"11","key":"990_CR38","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A department of veterans affairs cooperative study. Arthritis Rheum. 1999;42(11):2325\u20139.","journal-title":"Arthritis Rheum"},{"key":"990_CR39","doi-asserted-by":"crossref","unstructured":"Peluso R, Atteno M, Iervolino S, Bruner V, Caso F, Costa L et al. Methotrexate in the treatment of peripheral arthritis in ulcerative colitis. Reumatismo. 2011;61(1).","DOI":"10.4081\/reumatismo.2009.15"},{"key":"990_CR40","first-page":"175628482110057","volume":"14","author":"DT Rubin","year":"2021","unstructured":"Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, et al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Th Adv Gastroenterol. 2021;14:175628482110057.","journal-title":"Th Adv Gastroenterol"},{"issue":"7","key":"990_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","volume":"23","author":"SR Vavricka","year":"2017","unstructured":"Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis. 2017;23(7):1174\u201381.","journal-title":"Inflamm Bowel Dis"},{"key":"990_CR42","doi-asserted-by":"crossref","unstructured":"L\u00f6fberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn\u02bcs disease: results from CARE. Inflamm Bowel Dis. 2012;18(1).","DOI":"10.1002\/ibd.21663"},{"issue":"12","key":"990_CR43","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/ard.2003.012450","volume":"63","author":"S Generini","year":"2004","unstructured":"Generini S. Infliximab in spondyloarthropathy associated with crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63(12):1664\u20139.","journal-title":"Ann Rheum Dis"},{"key":"990_CR44","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Van Assche G, G\u00f3mez-Ulloa D, Garc\u00eda-\u00c1lvarez L, Lara N, Black CM et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15(1).","DOI":"10.1016\/j.cgh.2016.06.025"},{"issue":"Supplement1","key":"990_CR45","doi-asserted-by":"publisher","first-page":"i036","DOI":"10.1093\/ecco-jcc\/jjab232.032","volume":"16","author":"JF Colombel","year":"2022","unstructured":"Colombel JF, Cao Q, Ghosh S, Reinisch W, Zhou W, Ilo D, et al. OP33 effect of Upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe ulcerative colitis (UC): results from the UPA phase 3 programme. J Crohns Colitis. 2022;16(Supplement1):i036\u20137.","journal-title":"J Crohns Colitis"},{"key":"990_CR46","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.intimp.2022.108517","volume":"105","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, et al. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. Int Immunopharmacol. 2022;105:108517.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"990_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.33878\/2073-7556-2019-18-4-86-99","volume":"18","author":"EA Belousova","year":"2019","unstructured":"Belousova EA, Abdulganieva \u0412I, Alekseeva OP, Bakulin IG, Vasilyeva OV, Veselov AV, et al. EXPERIENCE OF TOFACITINIB USING IN THERAPY OF ULCERATIVE COLITIS IN REAL CLINICAL PRACTICE. Koloproktologia. 2019;18(4):86\u201399.","journal-title":"Koloproktologia"},{"issue":"11","key":"990_CR48","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/ibd\/izad075","volume":"29","author":"U Kopylov","year":"2023","unstructured":"Kopylov U, Burisch J, Ben-Horin S, Braegger F, Fern\u00e1ndez-Nistal A, Lara N, et al. Impact of Vedolizumab on extraintestinal manifestations in inflammatory bowel disease: results from a descriptive, retrospective, Real-world study. Inflamm Bowel Dis. 2023;29(11):1713\u201322.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"990_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/ueg2.12621","volume":"12","author":"S Rohekar","year":"2024","unstructured":"Rohekar S, Boyd T, Lambert RG, Beaton M, Chande N, Gregor J, et al. Initiation of Vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24\u2010week study with imaging assessments. United Eur Gastroenterol J. 2024;12(7):859\u201369.","journal-title":"United Eur Gastroenterol J"},{"key":"990_CR50","doi-asserted-by":"crossref","unstructured":"Feagan BG, Sandborn WJ, Colombel JF, O\u2019Byrne S, Khalid JM, Brayshaw N et al. DOP019 effect of Vedolizumab treatment on extraintestinal manifestations in patients with crohn\u2019s disease: a GEMINI 2 post hoc analysis. J Crohns Colitis. 2017;11(suppl_1).","DOI":"10.1093\/ecco-jcc\/jjx002.056"},{"key":"990_CR51","doi-asserted-by":"crossref","unstructured":"Guillo L, D\u2019Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for Extra-intestinal manifestations of inflammatory bowel disease: A systematic literature review. J Crohns Colitis. 2021;15(7).","DOI":"10.1093\/ecco-jcc\/jjaa260"},{"issue":"2","key":"990_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.gastha.2021.12.002","volume":"1","author":"D Lai","year":"2022","unstructured":"Lai D, Funez-dePagnier G, Duenas-Bianchi L, Lavergne A, Battat R, Ahmed W, et al. Joint disease activity in inflammatory bowel disease\u2013associated peripheral spondyloarthritis stratifies therapeutic response. Gastro Hep Adv. 2022;1(2):137\u201340.","journal-title":"Gastro Hep Adv"},{"issue":"1","key":"990_CR53","doi-asserted-by":"publisher","first-page":"e003977","DOI":"10.1136\/rmdopen-2023-003977","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Gossec L, Zimmermann M, Shawi M, Rampakakis E, Shiff NJ, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2024;10(1):e003977.","journal-title":"RMD Open"},{"issue":"3","key":"990_CR54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A Van den \u00d6st\u00f6r","year":"2022","unstructured":"Van den \u00d6st\u00f6r A, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of Risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 keepsake 2 trial. Ann Rheum Dis. 2022;81(3):351\u20138.","journal-title":"Ann Rheum Dis"},{"key":"990_CR55","doi-asserted-by":"crossref","unstructured":"n der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al. Efficacy and safety of Infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2).","DOI":"10.1002\/art.20852"},{"issue":"10349","key":"990_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Van den Deodhar","year":"2022","unstructured":"Van den Deodhar A, Poddubnyy D, van der Maksymowych WP, Kim TH, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10349):369\u201379.","journal-title":"Lancet"},{"issue":"8","key":"990_CR57","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"990_CR58","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, Schreiber S, D\u2019Haens G, Tanida S, et al. Efficacy of Upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139\u2013e214914.","journal-title":"Gastroenterology"},{"issue":"18","key":"990_CR59","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336.","journal-title":"N Engl J Med"},{"key":"990_CR60","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23).","DOI":"10.1056\/NEJMoa050516"},{"key":"990_CR61","doi-asserted-by":"crossref","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing crohn\u2019s disease. N Engl J Med. 2004;350(9).","DOI":"10.1056\/NEJMoa030815"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-00990-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-00990-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-00990-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:03:47Z","timestamp":1772579027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-00990-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-00990-8","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"KF receives grant funding from the Crohn\u2019s and Colitis Foundation (916943) and Pfizer (90146787). She served on an advisory panel for Janssen. MF consultant for BD Peripheral Vascular (Tempe, AZ) and Siemens Ultrasound (Issaquah, Washington). SC has no disclosures MEH consultant to Abbvie, BMS, Novartis, Eli Lilly, Janssen, and UCB, co-inventor PASE questionnaire receives royalties. Grant funded from the Arthritis Foundation and National Psoriasis Foundation and NIH. FR is a consultant to Adiso, Adnovate, Agomab, Allergan, AbbVie, Arena, Astra Zeneca, Bausch & Lomb, Boehringer-Ingelheim, Celgene\/BMS, Celltrion, CDISC, Celsius, Cowen, Eugit, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Landos, Jannsen, Koutif, Mestag, Metacrine, Mirum, Mopac, Morphic, Myka Labs, Organovo, Origo, Palisade, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, Trix Bio, UCB, Ysios, 89Bio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"52"}}